HUTCHINSON, Minn., March 7, 2011 (GLOBE NEWSWIRE) -- Hutchinson Technology Incorporated (Nasdaq:HTCH) today announced that it has received 510(k) clearance of the InSpectra™ StO2 Spot Check from the U.S. Food and Drug Administration. The product, which is targeted for use in emergency and critical care environments, is a cost-effective tool to help rapidly assess tissue perfusion and shock.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8837 .
The InSpectra StO2 Spot Check (model 300) consists of a hand-held device, cable, reusable sensor, charging station and rechargeable battery. This product enables clinicians to quickly and cost-effectively identify at-risk patients. Once identified as having low StO2, patients can then be continuously monitored with the InSpectra™ StO2 Tissue Oxygenation Monitor (model 650). These two products help reduce the time to critical actions and identify the endpoints of resuscitation."This is an exciting development for the assessment of critically ill patients," said Brahim Ardolic MD, Chair, Department of Emergency Medicine at Staten Island University Hospital (Staten Island, NY). "With Spot Check, we can quickly assess patients at increased risk of adverse effects due to decompensation of their status." "Multiple clinical studies demonstrate that patients with low StO2 are at risk of poor clinical outcomes and that 20-30% of emergency room and ICU patients have low StO2 even though other vital signs are normal," said Rick Penn, president of Hutchinson Technology's BioMeasurement Division. "In addition, recent research suggests that using StO2 to guide patient treatment results in improved clinical outcomes as well as economic benefits in the form of shorter length of stays in the ICU and the hospital."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV